Previous 10 | Next 10 |
MIAMI, April 17, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart ...
A look at the top 10 most actives in the United States PROSHARES TRUST (SQQQ) rose 5.1% to $11.44 on volume of 198,678,404 shares Trio Petroleum Corp. (TPET) rose 22.1% to $0.63 on volume of 179,140,668 shares Soligenix Inc. (SNGX) rose 21.7% to $0.47 on volume of 133,754,026 shares Sup...
2024-04-15 12:47:11 ET More on Mid-day movers & stocks. Enlivex stock plunges 50% on mixed results from sepsis study WiSA Technologies to effect 1-for-150 reverse stock split Seeking Alpha’s Quant Rating on BioSig Technologies, Inc. Historical earn...
A look at the top 10 most actives in the United States Soligenix Inc. (SNGX) rose 127.5% to $0.8782 on volume of 62,157,057 shares Trio Petroleum Corp. (TPET) rose 8.0% to $0.5571 on volume of 48,902,033 shares Organovo Holdings Inc. (ONVO) rose 36.3% to $1.3769 on volume of 34,819,187 sh...
2024-04-15 09:55:30 ET More on Longeveron Longeveron Inc. (LGVN) Q4 2023 Earnings Call Transcript Longeveron stock rallies 75% amid public offering, business update Seeking Alpha’s Quant Rating on Longeveron Historical earnings data for Longeveron ...
2024-04-15 08:41:18 ET More on premarket gainers & stock Carvana, Vroom, BuzzFeed, Encore Wire - Getting Paid To Take Risks With Courage & Conviction Investing U.S. Energy Corp. (USEG) Q4 2023 Earnings Call Transcript Cutera, Inc. (CUTR) Q4 2023 Earnings Call...
MIAMI, April 15, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it has been accepted for a Featured Research Oral Presentation to present the Company’s CLEAR MIND Phase 2a study...
Longeveron (NASDAQ: LGVN) , a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, has closed on its previo...
MIAMI, April 11, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart ...
Longeveron (NASDAQ: LGVN) , a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, has announced the pricin...
News, Short Squeeze, Breakout and More Instantly...
Longeveron Inc. Company Name:
LGVN Stock Symbol:
NASDAQ Market:
Longeveron (NASDAQ: LGVN) , a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, will be releasing its fi...
MIAMI, May 02, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will report first quarter 2024 financial results and provide a business update on Tuesday, May 14, 2024 after the U.S. fina...
Longeveron (NASDAQ: LGVN) , a clinical-stage, biotechnology company developing regenerative medicines, is one of 96 companies slated to participate at the Planet MicroCap Showcase: VEGAS. The three-day event begins in Las Vegas tomorrow and runs through May 2, 2024. The event kicks off with ...